US11680050 — Crystalline forms of ozanimod and ozanimod hydrochloride, and processes for preparation thereof
Method of Use · Assigned to Receptos LLC · Expires 2038-09-30 · 12y remaining
What this patent protects
This patent protects novel crystalline forms of ozanimod and ozanimod hydrochloride, which can be used to prepare drugs for treating autoimmune diseases.
USPTO Abstract
The present disclosure is directed to novel crystalline forms of ozanimod and ozanimod hydrochloride, as well as preparation method thereof. Said crystalline forms of ozanimod and ozanimod hydrochloride can be used for treating autoimmune diseases, particularly used for preparing drugs for treating multiple sclerosis and ulcerative colitis. The crystalline forms of the present disclosure have one or more advantages in solubility, melting point, stability, dissolution, bioavailability and processability and provide new and better choices for the preparation of ozanimod drug product, and are very valuable for drug development.
Drugs covered by this patent
FDA Patent Use Codes
When a patent is method-of-use, FDA lists it once per applicable indication ("U-code"). Each U-code carves out a specific therapeutic use that generic filers must either license or design around.
| Code | Description | Drug |
|---|---|---|
U-2774 |
— | ozanimod-hydrochloride |
U-2774 |
— | ozanimod-hydrochloride |
U-2774 |
— | ozanimod-hydrochloride |
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.